News from insightec ltd A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 30, 2014, 07:00 ET

InSightec Announces a New Series D Funding of $50 Million to Accelerate Market Development of MR-Guided Focused Ultrasound Noninvasive Treatments

InSightec, the global leader and pioneer in MR-guided focused ultrasound (MRgFUS) therapy for the non-invasive treatment of tumors, announced...

May 30, 2014, 06:44 ET

InSightec launches its first centers in China

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that the first centers in China offering ExAblate, for non-invasive...

May 08, 2014, 06:45 ET

Focused ultrasound for painful bone metastases provides durable pain relief and improved function

InSightec Ltd, the leader in magnetic resonance imaging guided Focused Ultrasound therapy (MRgFUS), announced that the results of its...

Nov 07, 2013, 11:19 ET

Robert Sigal kommt als Präsident und Chief Commercial Officer zu InSightec

InSightec Ltd, Marktführer bei der MRI-geführten fokussierten Ultraschalltherapie, kündigte heute an, dass Robert Sigal, MD, PhD,...

Nov 07, 2013, 11:07 ET

Robert Sigal rejoint InSightec en tant que président et directeur commercial

InSightec Ltd, le leader de la thérapie par ultrasons focalisés guidés par résonance magnétique (MRgFUS), a annoncé...

Nov 07, 2013, 11:03 ET

Robert Sigal entra in InSightec come Presidente e Chief Commercial Officer

InSightec Ltd, azienda leader nel campo degli Ultrasuoni Focalizzati guidati da Risonanza Magnetica (MRgFUS), ha annunciato che il Dott. Robert...

Nov 07, 2013, 06:10 ET

Robert Sigal Joins InSightec as President and Chief Commercial Officer

InSightec Ltd, the leader in MRI guided Focused Ultrasound therapy, announced that Robert Sigal, MD, PhD, will be joining InSightec as President...

Sep 10, 2013, 09:00 ET

First Patient Treated for Essential Tremor in Phase III Clinical Trial of ExAblate Neuro Focused Ultrasound System

InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro...

Aug 22, 2013, 08:00 ET

ExAblate Receives Approval of Health Canada for the Treatment of Uterine Fibroids and Pain Palliation of Bone Metastases

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that its ExAblate system received approval of Health Canada for...

Jul 29, 2013, 02:30 ET

ExAblate erhält Zustimmung der chinesischen Arzneimittelbehörde CFDA

Eine nicht-invasive MR-gesteuerte fokussierte Ultraschall-Behandlungsmethode ist nun Millionen von chinesischen Frauen zugänglich, die unter...

Jul 29, 2013, 02:30 ET

ExAblate goedgekeurd door Chinese Food and Drug Administration

Niet-invasieve, MR-geleide behandeling met gericht ultrageluid (Focused Ultrasound) beschikbaar voor miljoenen Chinese vrouwen die last hebben van...

Jul 29, 2013, 02:30 ET

ExAblate riceve l'approvazione dall' Agenzia per gli Alimenti e i Medicinali, cinese

La terapia non-invasiva con ultrasuoni focalizzati guidata in RM è ora disponibile per milioni di donne cinesi che soffrono di fibromi...

Jul 29, 2013, 02:30 ET

ExAblate Receives Approval of Chinese Food and Drug Administration

Non-invasive MR guided Focused Ultrasound treatment now available for millions of Chinese women suffering from uterine fibroids InSightec Ltd,...

Jul 01, 2013, 14:54 ET

ExAblate riceve la certificazione estesa per il marchio CE per tumori delle ossa benigni e cancerogeni

 --Le indicazioni comprendono il trattamento delle metastasi delle ossa, il mieloma multiplo, osteoma osteoide, faccette articolari,...

Jul 01, 2013, 10:07 ET

ExAblate obtient un marquage CE étendu pour le traitement des tumeurs osseuses bénignes et cancéreuses

  -- Au nombre de ses indications figure le traitement des métastases osseuses, du myélome multiple, de l'ostéome...

Jul 01, 2013, 08:18 ET

ExAblate erhält erweiterte CE-Kennzeichnung zur Behandlung gutartiger und bösartiger Knochentumore

-- Zu den Indikationen zählt die Behandlung von Knochenmetastasen, multiplen Myelomen, Osteoidosteomen, Facettengelenken und sonstigen...

Jul 01, 2013, 05:25 ET

ExAblate recibe el certificado ampliado de la marca CE para los tumores óseos cancerígenos y benignos

-- Las indicaciones incluyen el tratamiento de las metástasis óseas, mieloma múltiple, osteoma osteoide, articulaciones facetarias...

Apr 18, 2013, 09:00 ET

Medicare Establishes Billing Code and Payment for InSightec's MR guided Focused Ultrasound (MRgFUS) Therapy for Pain Palliation of Bone Metastases

InSightec Ltd. announced today that the US Centers for Medicare & Medicaid Services (CMS), a federal agency within the US Department of Health...

Feb 19, 2013, 09:21 ET

InSightec's ExAblate Neuro Receives the Go-ahead from FDA to Begin its Pivotal Phase III trial for Essential Tremor

InSightec Ltd announced that it has received FDA approval to begin its pivotal Phase III clinical trial for treatment of essential tremor using...

Dec 09, 2012, 04:05 ET

InSightec completes additional financing round of $30.9 million

 InSightec Ltd. announced that it has completed its Series C financing totaling $30.9 million. In parallel, the Board of Directors has...